cerebral ischemic stroke
Conditions
Interventions
Group A:Aspirin 100mg orally taken once daily and Ginkgo biloba extract dispersible tablets 0.15g orally three times daily
Group B:Aspirin 100mg orally taken once daily
Sponsors
Department of Neurology, Affiliated Drum Tower Hospital of Nanjing University Medical School
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Adult men and women 18-80 years old; 2. Acute ischemic stroke within 72 hours verified by imaging; 3. Have NIH Stroke Scale (NIHSS) score of 4-20 inclusive and modified Rankin scale score of 0-3 inclusive at screening; 4. People who need anti-platelet drugs therapy; 5. First-onset patients or recrudescent patients who NIHSS<4 in past history; 6. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Have history of intracranial hemorrhage or subarachnoid hemorrhage; 2. Cardiogenic cerebral embolism; 3. Terminal stage of severe disability or illness; 4. Have contraindication of anti-platelet therapy, or use other anti-platelet drug during the trial; 5. Have severe cardiac, hepatic or renal insufficiency. Total bilirubin > 1.5 times of upper normal limit, AST or ALT > 2.5 times of upper normal limit; 6. Have pulmonary infection, or severe systemic infection; 7. Have history of severe allergic reactions, or allergic to drugs or food (>=2), or those have immunization history in half a year; 8. Have symptom of intracranial hypertension which induced by organic disease of brain, such as brain tumor; 9. Have serum HIV, TPHA positive, or suffered from hepatitis B or hepatitis C; 10. Have severe mental disorder with cognitive impairment, or not able to understand and sign consent; 11. Have coagulation defects 12. Have uncontrolled hypertension, after treatment the blood pressure>=180/110mmHg; uncontrolled severe diabetes mellitus; Complicate with other diseases which influence activities of limbs such as claudication, osteoarthritis, rheumatoid arthritis or gouty arthritis; 13. Achieved in the prior informed consent within 3 months of participation in other clinical research; 14. Researchers recorgnized anyone who is not suitable to participate in this clinical study of patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| platelet aggregation test;Occurrence rate of the primary endpoint and combined endpoint; | — |
Countries
China
Contacts
Public ContactYun Xu
Outcome results
None listed